Skip to main content
24 search results for:

Lorlatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 12-01-2023 | Non-small-cell lung cancer | News | Article
    News in brief

    CROWN update confirms long-term lorlatinib PFS benefit

    Lorlatinib offers a “durable benefit” for the first-line treatment of advanced ALK -positive non-small-cell lung cancer, indicates a 3-year update from the CROWN trial.

  2. 20-06-2022 | Non-small-cell lung cancer | News | Article

    Lorlatinib benefits extend to NSCLC patients with brain metastases

    Patients with advanced ALK- positive non-small-cell lung cancer derive prolonged progression-free survival from first-line treatment with lorlatinib regardless of the presence of brain metastases, post-hoc analyses indicate.

  3. 22-12-2021 | EMA | News | Article

    Tepotinib, lorlatinib receive EMA nod

    Previously lorlatinib could only be given to patients who had either received alectinib or ceritinib as their first ALK–TKI, or crizotinib and at least one other ALK–TKI.

  4. 07-02-2022 | Non-small-cell lung cancer | News | Article
    News in brief

    Continuing lorlatinib beyond progression beneficial for some ALK-positive NSCLC patients

    Analysis of data from the pivotal phase 2 trial of lorlatinib points to the benefit of continuing treatment with the third-generation ALK inhibitor beyond progression in some patients with advanced non-small-cell lung cancer positive for ALK translocations.

  5. 11-01-2022 | Lorlatinib | Adis Journal Club | Article
    European Journal of Drug Metabolism and Pharmacokinetics

    A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment

    Conclusion Lorlatinib 100 mg was well tolerated.

  6. 05-03-2021 | FDA | News | Article
    approvalsWatch

    Lorlatinib gains first-line NSCLC indication in USA

    medwireNews : Lorlatinib can now be used for the frontline treatment  of individuals with metastatic non-small-cell lung cancer (NSCLC) harboring ALK translocations, says the US FDA.

  7. 29-09-2020 | ESMO 2020 | Conference coverage | Article

    Lorlatinib shows substantial benefits over crizotinib for ALK-positive NSCLC

    First-line treatment with lorlatinib significantly improves progression-free survival, relative to crizotinib, in patients with advanced ALK- positive, non-small-cell lung cancer, results of the phase 3 CROWN study show.

  8. play
    22-09-2020 | ESMO 2020 | Conference coverage | Video

    Lorlatinib takes CROWN in head-to-head comparison with crizotinib

    Benjamin Solomon highlights the key messages of the CROWN study of lorlatinib in advanced, ALK-positive non-small-cell lung cancer and makes the case for using the agent upfront in these patients.

  9. 12-04-2019 | Non-small-cell lung cancer | News | Article

    ALK resistance mutations predict lorlatinib efficacy in NSCLC patients progressing on ALK–TKIs

    Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.

  10. 05-03-2019 | EMA | News | Article
    approvalsWatch

    Lorlatinib given European NSCLC approval

    Lorlatinib has previously been approved for these indications by the US FDA .

  11. 01-11-2019 | Non-small-cell lung cancer | News | Article

    Further data support lorlatinib as an option in advanced ROS1-positive NSCLC

    The early potential of lorlatinib for the treatment of patients with advanced ROS1 -positive non-small-cell lung cancer who are either tyrosine kinase inhibitor-naïve or have previously received crizotinib has been re-emphasized in the expanded analysis of a phase I–II trial.

  12. 03-12-2018 | FDA | News | Article
    approvalsWatch

    Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

    By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group See also: Lorlatinib active against ALK, ROS1-rearranged NSCLC

  13. 13-11-2018 | Non-small-cell lung cancer | News | Article

    Lorlatinib shows promising activity against ALK-positive advanced NSCLC

    Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

  14. 22-06-2018 | Non-small-cell lung cancer | ASCO 2018 | Article
    News in brief

    Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC

    The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer patients with heavily pretreated, advanced ALK -positive disease.

  15. 01-11-2017 | Non-small-cell lung cancer | News | Article

    Lorlatinib active against ALK, ROS1-rearranged NSCLC

    Approximately half of patients with anaplastic lymphoma kinase or ROS proto-oncogene 1 rearranged non-small-cell lung cancer respond to treatment with lorlatinib, show results of a first-in-human dose escalation study.

  16. 16-08-2022 | WCLC 2022 | Conference coverage | Article

    Entrectinib shows potential as first-line treatment for ROS1 fusion-positive advanced NSCLC

    Session discussant Lorenza Landi (‘Regina Elena’ National Cancer Institute, Rome, Italy) said that the exploratory analysis for the efficacy of first-line entrectinib was “very new” because earlier trials in the ROS1 fusion-positive setting of crizotinib, ceritinib, and lorlatinib were all conducted in patients who had previously received chemotherapy.

  17. 11-04-2022 | ALK-mutated NSCLC | Interview | Article

    Pathologic testing for ALK and ROS1 aberrations in NSCLC

    For ROS1, the first-line treatment is usually based on crizotinib and the second line on lorlatinib or on entrectinib.

  18. 13-01-2022 | ALK-mutated NSCLC | Adis Journal Club | Article
    Targeted Oncology

    Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

    Drug discontinuation was recorded in 31.6% of the reported cases, with the highest proportion for lorlatinib (65.4%).

  19. 04-05-2021 | Lung and thoracic tumors | At a glance | Article

    At a glance: The JAVELIN lung cancer trials

    Related news story: No survival benefit seen with avelumab in advanced PD-L1-positive NSCLC   JAVELIN Lung 101: Ongoing   Phase 1b/2 Patient population: Locally advanced or metastatic NSCLC Treatments: Avelumab 5 or 10 mg/kg once every 2 weeks plus either crizotinib 200 or 250 mg once or twice a day or lorlatinib 50, 75, or 100 mg once a day Sponsor: Pfizer https://clinicaltrials.gov/ct2/show/NCT02584634 Initial results from the phase 1b part of the study, reported at the 2018 ASCO Annual Meeting , showed that avelumab plus lorlatinib has a manageable safety profile and promising efficacy among ALK -positive NSCLC patients previously treated with any number of ALK inhibitors.

  20. 02-10-2019 | Non-small-cell lung cancer | Video | Article

    Expert highlights: Lung and thoracic cancers at ESMO 2019

    Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.